Stay updated with breaking news from Gray Cap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third)
FDA also authorizes second booster dose for individuals 12 years of age and older who have certain kinds of immunocompromise Second booster dose is intended to offer increased protection against
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses as part of a three-dose
European Commission exercise part of its option for over 200 million additional doses to be delivered in 2022 These doses are in addition to the 450 million doses already planned for delivery